Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2023-03-28 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
[기재정정]전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samchundang Pharm regarding the exercise of conversion rights (conversion of convertible bonds into shares). This type of filing, which details changes in capital structure due to the conversion of debt into equity, falls under the category of share issues or capital changes. In the provided taxonomy, 'SHA' (Share Issue/Capital Change) is the most appropriate classification for announcements regarding new share issues resulting from convertible bond exercises.
2023-03-28 Korean
투자판단관련주요경영사항(아일리아 바이오시밀러(SCD411) 임상 3상 결과 발표)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Samchundang Pharm regarding the results of a Phase 3 clinical trial for their biosimilar product (SCD411). It follows the standard format for a 'Major Management Matter' (투자판단 관련 주요경영사항) filing in the Korean market, which is used to announce significant corporate developments such as clinical trial outcomes. Since it does not fit into specific categories like financial reports, dividend notices, or board changes, and is a direct regulatory disclosure of material information, it is classified as a Regulatory Filing (RNS).
2023-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It contains key financial data, audit opinions, and financial statements for the fiscal year. While it provides financial data, it is a standardized regulatory disclosure form rather than a full 10-K annual report or a standalone audit report document. Given the structure and the nature of the disclosure, it fits best under the 'Regulatory Filings' category as a formal announcement of the audit results. FY 2022
2023-03-21 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 79th fiscal year, covering the period from January 1, 2022, to December 31, 2022. It includes detailed sections on company overview, history, capital changes, and shareholding information, which are standard components of a comprehensive annual report (10-K equivalent in the Korean market). FY 2022
2023-03-21 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Samchundang Pharm Co., Ltd. It contains the meeting agenda, voting procedures, and detailed financial statements (balance sheet, income statement, statement of changes in equity) for the 79th fiscal year. While it contains financial data, it is primarily a proxy solicitation document sent to shareholders to inform them of the upcoming AGM and request their votes (including electronic voting instructions). According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category, as it serves to provide information and request votes for the meeting.
2023-03-10 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Samchundang Pharm. It outlines the date, location, and agenda items (such as approval of financial statements and director compensation) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders, which falls under the Proxy Solicitation & Information Statement category.
2023-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.